2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer - Takeaways - MDSpire

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

October 15, 2026

Dana-Farber

Share

1

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss first-line treatment options for triple-negative breast cancer.
2

The discussion focuses on new antibody-drug conjugate treatment options.
3

The context identifies the topic as triple-negative breast cancer.
4

The discussion is presented as part of the 2026 ASCO Breast Cancer Highlights.
5

The provided context does not specify particular antibody-drug conjugates or clinical findings.

Original Source(s)

Dana-Farber

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

October 15, 2026

Related Content

Dana-Farber

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.